The global DNA sequencing market is projected to have a steady growth rate over the forecast period. Demand for accurate, inexpensive and fast DNA sequencing data has led to the evolution and dominance of a new generation of sequencing technologies. DNA sequencing can be defined as any biochemical method for determining the order of nucleotide bases, thymine, cytosine, guanine and adenine in a DNA nucleotide. DNA sequencing contains information about personality traits, genetically determined illness and IQ level of a human being. Therefore, determining legality, ethics and security concerning control and storage of that data are paramount. The use of genetic information has the potential to provide individuals and medical professionals with an arsenal of life impacting information. In addition, different sciences are receiving benefits of this technique, including forensic sciences, molecular biology, biotechnology, genetics, anthropology and archaeology.
DNA sequencing is expected to revolutionize the conceptual foundation of these fields. However, issues related to public health and safety could pose a challenge to the DNA sequencing market growth. The first method described for DNA sequencing was called plus and minus (Sangers) method. However due to ineffiency of this method, the manufacturers described a breakthrough method for sequencing oligonucleotides via enzymic polymerization. The enzymic method for DNA sequencing has been used for genomics research as the main tool to generate the fragments necessary for sequencing, regardless of the sequencing strategies. Since completion of the first human genome sequence, demand for a faster and cheaper sequencing method has increased greatly. This demand has driven the development of second generation sequencing method or next generation sequencing (NGS). This method is expected to revolutionize the field of genomics in the forecast period. Despite opening new edge of genomics research, the fundamental shift away from the conventional sequencing to the NGS technologies has left many undiscovered applications and capabilities of these new technologies, especially those in clinical segment. In addition, the evolution of new sequencing technologies has raised the demand for commercially available platforms, whose diverse applications are restricting the potential of NGS for clinical research and physician scientists.
The global DNA sequencing market can be segmented into workflow, services, instruments and consumable products. Constant technological changes and creation of new opportunities are expected to attract new market players to the DNA sequencing industry. The current breakthrough in micro fluidics, nanotechnology, imaging and bioinformatics are expected to provide a novel platform for NGS market.
Major industry participants include ZS Genetics, Siemens AG, Pacific Biosciences, Myriad Genetics, Microchip Biotechnologies, Johnson & Johnson, Integrated DNA Technologies, Hamilton Thorne Biosciences, Commonwealth Biotechnologies, Bayer Corporation, Agilent Technologies, Abbott Laboratories, Abbott Laboratories, LI-COR Biosciences, GE Healthcare Life Sciences and 454 Life Sciences.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.